Logo image
Back
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline
Journal article   Open access   Peer reviewed

Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline

Joanne Ryan, Elsdon Storey, Anne M. Murray, Robyn L. Woods, Rory Wolfe, Christopher M. Reid, Mark R. Nelson, Trevor T. J. Chong, Jeff D. Williamson, Stephanie A. Ward, …
Neurology, Vol.95(3), pp.E320-E331
07/21/2020
DOI: 10.1212/WNL.0000000000009277
PMCID: PMC7455352
PMID: 32213642
url
https://doi.org/10.1212/WNL.0000000000009277View
Published (Version of record) Open Access

Abstract

Objective To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals. Methods Aspirin in Reducing Events in the Elderly (ASPREE) was a double-blind, placebo-controlled trial of low-dose aspirin. In the United States and Australia, community-dwelling individuals aged >= 70 years (US minorities >= 65 years) and free of cardiovascular disease, physical disability, and diagnosed dementia were enrolled. Participants were randomized 1:1-100 mg daily aspirin or placebo. The Modified Mini-Mental State Examination, Hopkins Verbal Learning Test-Revised, Symbol Digit Modalities Test, and Controlled Oral Word Association Test assessed cognition at baseline and over follow-up. Additional cognitive testing was performed in participants with suspected dementia ("trigger") based on within-study assessments or clinical history. Dementia was adjudicated according to DSM-IV criteria. National Institute on Aging-Alzheimer's Association criteria were used for AD and MCI subclassification. Results A total of 19,114 participants were followed over a median 4.7 years and 964 triggered further dementia assessments. There were 575 adjudicated dementia cases, and 41% were classified as clinically probable AD. There was no substantial difference in the risk of all dementia triggers (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.91-1.17), probable AD (HR, 0.96; 95% CI, 0.74-1.24), or MCI (HR, 1.12; 95% CI, 0.92-1.37) between aspirin and placebo. Cognitive change over time was similar in the aspirin and placebo groups. Conclusions There was no evidence that aspirin was effective in reducing risk of dementia, MCI, or cognitive decline. Follow-up of these outcomes after initial exposure is ongoing. Classification of evidence This study provides Class II evidence that for healthy older individuals, low-dose aspirin does not significantly reduce the incidence of dementia, probable AD, MCI, or cognitive decline. Clinicaltrials.gov identifier NCT01038583.
 Clinical Neurology Life Sciences & Biomedicine Neurosciences & Neurology Science & Technology

Details

Metrics

23 Record Views
142 Times Cited - Web of Science
Logo image